Aratana Therapeutics Inc (NASDAQ:PETX) shot up 3.9% during mid-day trading on Wednesday . The company traded as high as $6.75 and last traded at $6.73, with a volume of 432,962 shares trading hands. The stock had previously closed at $6.48.

A number of brokerages have issued reports on PETX. Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a research report on Wednesday, July 20th. Credit Suisse Group AG restated a “buy” rating on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Lake Street Capital restated a “buy” rating and set a $15.00 price objective on shares of Aratana Therapeutics in a research report on Sunday, July 17th. Jefferies Group restated a “buy” rating and set a $12.00 price objective on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Finally, William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $11.66.

The stock has a 50-day moving average of $6.55 and a 200 day moving average of $5.34. The stock’s market cap is $242.13 million.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.10. During the same quarter last year, the firm posted ($0.26) EPS. The company earned $0.17 million during the quarter, compared to the consensus estimate of $0.13 million. The company’s revenue was up 6.3% compared to the same quarter last year. Equities analysts expect that Aratana Therapeutics Inc will post ($1.02) EPS for the current year.

In related news, CEO Peter Steven St sold 100,000 shares of Aratana Therapeutics stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $6.26, for a total value of $626,000.00. Following the sale, the chief executive officer now directly owns 717,793 shares in the company, valued at approximately $4,493,384.18. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Ernst Heinen sold 15,000 shares of Aratana Therapeutics stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $6.72, for a total value of $100,800.00. Following the completion of the sale, the insider now owns 125,494 shares in the company, valued at $843,319.68. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Aratana Therapeutics stock. Jennison Associates boosted its stake in Aratana Therapeutics Inc (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned about 11.84% of Aratana Therapeutics worth $35,077,000 at the end of the most recent quarter.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.